The latest updates you cannot miss.
End of Year Edition
Charles Kumps recently stepped into the role of Vice President of IBA RadioPharma Solutions
He is very pleased to have joined the team and to carry forward the projects for the coming years with all the exciting developments that we have ahead.
New Revolutionizing Innovation: Discover our game-changing Helium Free Target!
We are proud to launch our Helium cooling free target, designed to meet your needs and improve sustainability.
The promises of our Nirta® HeFree target:
- Boosted productivity: Achieve up to 20% higher yield per run
- Enhanced safety: No activated parts remain on the cyclotron and maintenance occurence reduced by half
- Cost efficiency: Reduce operational costs by using up to 50% less enriched water and no Helium at all, not even for pressurization
In November we had the pleasure to finalize the rigging of the Cyclone® IKON at CNRT in China!
CNRT and IBA have successfully rigged a 30 MeV cyclotron, Cyclone® IKON, in Chengdu, Sichuan, China.
With this major milestone, this high-energy cyclotron will enable CNRT to accelerate the research and development of future radionuclides, ensuring the production of reliable radiopharmaceuticals for precision therapies.
It includes the production of Zirconium-89, Copper-64, Fluorine-18, Iodine-123, Germanium-68 and many more.
New IBA Kare Portal: Unlock your potential. Anytime. Anywhere.
Explore our new platform, IBA Kare Portal, and get closer to your team, your equipment and our customer services.
Is cardiac PET imaging revolutionizing cardiovascular medicine around the world?
Don't miss out on our latest on-demand webinar with world renowned experts, Prof Dr Marcelo Di Carli and Dr Parthiban Arumugam. Discover why this non-invasive medical imaging technique is a game-changer for early diagnosis and precise monitoring of cardiovascular diseases, especially coronary artery disease.
Watch the highlights of our latest Users' Meeting
We are excited to share the highlights of yet another successful Users' Meeting in this amazing video!
Thank you for joining and making this Users' Meeting a success. We loved to see you share your experience with your peers from around the world.
[18F]FES /16α-[18F]-fluoroestradiol
Radiolabeled analog of estradiol is used as a PET imaging probe for estrogen receptor-positive breast cancer lesions.
To ensure that the obtained product meets quality control requirements for drug release we decided to use high pressure liquid chromatography purification (HPLC).
Automated labeling of flotufolastat gallium triflutate with 18F on the IBA Synthera®+ Platform - a simplified and efficient approach*
Diagnostic 18F-flotufolastat enables high-resolution PET imaging of PSMA-expressing lesions. Its favorable positron energy and longer half-life (109.8 minutes – comparing to 68Ga-labeled compounds) enhance image quality and sensitivity. Approved by the FDA for commercial use.
AlF-peptides labelling method - One process to label them all…
IBA intends to propose commercial kits for AlF-peptide process on Synthera®+ (IFP, reagents, ancillaries).
Simplified preparation. Better controlled dilution (critical step). Standard size vials. Efficient, fast and robust
Find out at which events to meet us next
* DISCLAIMER: 18F-flotufolastat is approved in the United States by the FDA and is not currently approved in other jurisdictions. This is a proprietary tracer. To access it, users must obtain authorization from Blue Earth Diagnostics Ltd.